Physician profile
Andrew C Campbell
NPI 1134238926
$153,345.90
in general payments reported to CMS, 2019-2025
5 companies · $13K in 2025
The $13K reported for 2025 was more than what 98% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $5,493 · 2021: $3,664 · 2022: $87K · 2023: $39K · 2024: $4,056 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $21K · Food and Beverage: $1,990 · Travel and Lodging: $1,547 · Long Term Medical Supply Or Device Loan: $1,102 · Education: $76.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,831.46 |
| Consulting Fee | $20,700.00 |
| Food and Beverage | $1,989.54 |
| Travel and Lodging | $1,546.61 |
| Long Term Medical Supply Or Device Loan | $1,102.05 |
| Education | $76.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $94,654.96 | 2019-2022 | |
| Abbvie INC. | $54,782.50 | 2023-2025 | Botox |
| Galderma Laboratories, L.P. | $2,646.88 | 2020-2025 | Dysport |
| Integra Lifesciences Corporation | $1,102.05 | 2024-2025 | Durasorb Monofilament Mesh |
| Merz North America, INC. | $159.51 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.